Market Closed -
Nasdaq Stockholm
11:29:31 2024-04-26 EDT
5-day change
1st Jan Change
373
SEK
+4.63%
+17.85%
+13.20%
Sales 2024 *
795M
72.65M
99.32M
Sales 2025 *
1.1B
101M
138M
Capitalization
11.75B
1.07B
1.47B
Net income 2024 *
78M
7.13M
9.75M
Net income 2025 *
165M
15.08M
20.62M
EV / Sales 2024 *
14.2
x
Net cash position
2024
*
425M
38.87M
53.15M
Net cash position
2025
*
418M
38.23M
52.27M
EV / Sales 2025 *
10.3
x P/E ratio 2024 *
159
x
P/E ratio 2025 *
73.6
x
Employees
148
Yield 2024 *
-
Yield 2025 *
-
Free-Float
75.13%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest
04-24
DJ
Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024
04-24
Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2024
04-24
CI
Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague
04-11
CI
Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 16-MAR-2024.
03-15
CI
Nordic Shares Moved Upward Thursday; Nokia Topped Leaders
01-25
DJ
Transcript : Xvivo Perfusion AB, 2023 Earnings Call, Jan 25, 2024
01-25
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023
01-25
CI
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
01-25
CI
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss
01-17
DJ
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published
11-03
CI
Transcript : Xvivo Perfusion AB, Q3 2023 Earnings Call, Oct 24, 2023
23-10-24
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-24
CI
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial
23-10-23
CI
Xvivo Perfusion AB Announces Appointment of Members of Nomination Committee
23-09-29
CI
More news
LE OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Boreo, Fugro, STMicroelectronics, Alfen, Iberdrola, Roche, Temenos, Akzo Nobel...
04-25
AVIS D'ANALYSTES DU JOUR : Kering, Carrefour, STMicroelectronics, ArgenX, Ipsen, Accor, Moncler...
04-25
OPINIONES DE LOS ANALISTAS DEL DÍA : Aedas Homes, Almirall, STMicroelectronics, Enagás, Iberdrola, Roche, Temenos, Moncler...
04-25
Les actions en mouvement : Vetoquinol et Teleperformance coulent, Vusiongroup et ID Logistics brillent
01-25
More news 1 day +4.63%
1 week +17.85%
Current month +35.64%
1 month +36.63%
3 months +29.07%
6 months +64.68%
Current year +13.20%
More quotes
Managers
Title Age Since
Chief Executive Officer
49
12-08-31
Director of Finance/CFO
39
-
Chief Tech/Sci/R&D Officer
57
20-09-30
Members of the board
Title Age Since
Director/Board Member
60
16-04-30
Chairman
65
-
Director/Board Member
69
19-12-31
More insiders
Date
Price
Change
Volume
24-04-26
373
+4.63%
66,306
24-04-25
356.5
-3.26%
120,578
24-04-24
368.5
+14.80%
302,535
24-04-23
321
+2.23%
30,602
24-04-22
314
-0.79%
23,587
Delayed Quote
Nasdaq Stockholm, April 26, 2024 at 11:29 am
More quotes
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Companyâs product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
More about the company
Average target price
408
SEK
Spread / Average Target
+9.38%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1